What amount sold does NOVADIGM THERAPEUTICS INC report in Form D filings?

The latest linked filings report $7M sold across 1 identified offering(s). 3 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was NOVADIGM THERAPEUTICS INC's most recent SEC filing?

NOVADIGM THERAPEUTICS INC's most recent Form D filing was on 2013-10-03.

How many investors does NOVADIGM THERAPEUTICS INC have?

The most recent Form D filing lists 5 investor(s).

What type of securities does NOVADIGM THERAPEUTICS INC offer?

NOVADIGM THERAPEUTICS INC's SEC Form D filings indicate equity offerings.

NOVADIGM THERAPEUTICS INC

CIK: 0001439464·Biotechnology·GRAND FORKS, ND·Corporation·Founded 2009

Reported Sold

$7,013,058

Total Filings

Identified Offerings

Last Filed

Oct 3, 2013

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 3 unlinked amendments excluded.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Oct 3, 2013Form D — New notice

Reported sold: $7,013,058 · Target: $25,000,000

Rule 506(b)·5 investors

Feb 20, 2013Form D/A — Amendment

Reported sold: $20,588,274 · Target: Indefinite

Rule 506·4 investors

Changed: Reported amount sold

Oct 20, 2011Form D/A — Amendment

Reported sold: $10,585,916 · Target: Indefinite

Rule 506·4 investors

Changed: Reported amount sold

Dec 16, 2009Form D/A — Amendment

Reported sold: $6,585,916 · Target: Indefinite

No verified predecessor available.

Rule 506·4 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

75%

Latest reported sold across 1 identified offering

$7,013,058

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

3 unlinked amendments excluded.

Key People

Michael Timothy Cooke

Related Person

Appears on 2 filings

Tuomas Holmberg

Related Person

Appears on 2 filings

Gordon Douglas

Related Person

Appears on 2 filings

Boyd Clark

Related Person

Appears on 2 filings

Todd Brady

Related Person

Appears on 2 filings

Fred Haney

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 3, 2013	New	$25,000,000	$7,013,058	5
Feb 20, 2013	Amendment	Indefinite	$20,588,274	4
Oct 20, 2011	Amendment	Indefinite	$10,585,916	4
Dec 16, 2009	Amendment	Indefinite	$6,585,916	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Nuclein, LLC

Biotechnology

Offering target: $26,114,842

Filed Oct 27, 2026